Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 1,381–1,390 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 1381
- Medicine slug
- scopolamine
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
9.5 hours
- Numeric value
- 9.5
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a472ee74-76a7-470f-8564-9018940a82e8 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d8332e-b8d2-4d13-8071-978d57e51928 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5aa64f85-ae52-4a86-a894-a4e536fbe4ad (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b24c2315-c947-4ad2-89fe-8dc0c45e221b (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b877a694-a1d0-4280-937a-a06820b12a88 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd031a59-6b8c-49b1-9b4d-e7a7b75e3801 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51289d8b-f7e3-a3e0-e063-6294a90add43 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba5a1237-4d23-441a-808e-96b97045fbe2 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48e6e53a-d904-475b-84dd-6068cc0cb36b (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800b6421-48eb-47f5-b255-c12f75e59068 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d53ee59-e0ef-4332-a6d6-0ac5a6c21b55 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163accb7-45e6-4d97-844d-72b606677008 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c232a94-0842-4efc-98a6-9d23e3b15a76 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a6f9aaf-a70a-481f-a82b-1dcaaadc185b (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Following transdermal system removal, plasma concentrations of scopolamine decline in a log linear fashion with an observed half-life of 9.5 hours.
Projected row 1382
- Medicine slug
- scopolamine
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 14
- Source count
- 14
- Agreement rate
- 1
- Recorded readings
24 hours
- Numeric value
- 24
- Unit
- hours
- Source records
- 14
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 14 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a472ee74-76a7-470f-8564-9018940a82e8 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:62d8332e-b8d2-4d13-8071-978d57e51928 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5aa64f85-ae52-4a86-a894-a4e536fbe4ad (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b24c2315-c947-4ad2-89fe-8dc0c45e221b (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b877a694-a1d0-4280-937a-a06820b12a88 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dd031a59-6b8c-49b1-9b4d-e7a7b75e3801 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51289d8b-f7e3-a3e0-e063-6294a90add43 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ba5a1237-4d23-441a-808e-96b97045fbe2 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48e6e53a-d904-475b-84dd-6068cc0cb36b (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:800b6421-48eb-47f5-b255-c12f75e59068 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8d53ee59-e0ef-4332-a6d6-0ac5a6c21b55 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:163accb7-45e6-4d97-844d-72b606677008 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5c232a94-0842-4efc-98a6-9d23e3b15a76 (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2a6f9aaf-a70a-481f-a82b-1dcaaadc185b (opens source in a new tab)
Scopolamine label
Version not recorded · Effective date not recorded
Absorption Following application to the skin behind the ear, circulating plasma concentrations are detected within 4 hours with peak concentrations being obtained, on average, within 24 hours.
Projected row 1383
- Medicine slug
- selexipag
- Compared field
- bioavailability
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
49%
- Numeric value
- 49
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c604e181-e336-4194-bf96-f65dd164d461 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of orally administered selexipag is approximately 49%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7a23b87-f892-4e2c-8e2e-ebf841220f90 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of orally administered selexipag is approximately 49%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff660787-880f-4f2b-baac-fd2dbfcd79c2 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Absorption The absolute bioavailability of orally administered selexipag is approximately 49%.
Projected row 1384
- Medicine slug
- selexipag
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
0.8 to 2.5 hours
- Numeric value
- 0.8
- Unit
- hours
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c604e181-e336-4194-bf96-f65dd164d461 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Elimination Elimination of selexipag is predominately via metabolism with a mean terminal half-life of 0.8 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7a23b87-f892-4e2c-8e2e-ebf841220f90 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Elimination Elimination of selexipag is predominately via metabolism with a mean terminal half-life of 0.8–2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff660787-880f-4f2b-baac-fd2dbfcd79c2 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Elimination Elimination of selexipag is predominately via metabolism with a mean terminal half-life of 0.8 to 2.5 hours.
Projected row 1385
- Medicine slug
- selexipag
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c604e181-e336-4194-bf96-f65dd164d461 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Selexipag and its active metabolite are highly bound to plasma proteins (approximately 99% in total and to the same extent to albumin and alpha1-acid glycoprotein).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7a23b87-f892-4e2c-8e2e-ebf841220f90 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Selexipag and its active metabolite are highly bound to plasma proteins (approximately 99% in total and to the same extent to albumin and alpha1-acid glycoprotein).
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff660787-880f-4f2b-baac-fd2dbfcd79c2 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Selexipag and its active metabolite are highly bound to plasma proteins (approximately 99% in total and to the same extent to albumin and alpha1-acid glycoprotein).
Projected row 1386
- Medicine slug
- selexipag
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 3
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
11.7 L
- Numeric value
- 11.7
- Unit
- L
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c604e181-e336-4194-bf96-f65dd164d461 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of selexipag at steady-state is 11.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a7a23b87-f892-4e2c-8e2e-ebf841220f90 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of selexipag at steady-state is 11.7 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ff660787-880f-4f2b-baac-fd2dbfcd79c2 (opens source in a new tab)
Selexipag label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of selexipag at steady-state is 11.7 L.
Projected row 1387
- Medicine slug
- semaglutide
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 5
- Source count
- 5
- Agreement rate
- 0.8
- Recorded readings
89%
- Numeric value
- 89
- Unit
- %
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:42bdd912-2393-44c4-b7e0-47672ca28991 (opens source in a new tab)
Semaglutide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Absolute bioavailability of semaglutide is 89%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6da837c-0da0-41d6-973c-5559bf764367 (opens source in a new tab)
Semaglutide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Absolute bioavailability of semaglutide is 89%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f5e548d0-cc79-4c34-a3f5-e20a5b8b6564 (opens source in a new tab)
Semaglutide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Absolute bioavailability of semaglutide is 89%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:979e4df4-0597-48ea-b51c-0f699fa6d166 (opens source in a new tab)
Semaglutide label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Absorption Absolute bioavailability of semaglutide is 89%.
0.4%
- Numeric value
- 0.4
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:27f15fac-7d98-4114-a2ec-92494a91da98 (opens source in a new tab)
Semaglutide label
Version not recorded · Effective date not recorded
Semaglutide estimated absolute bioavailability was approximately: • 0.4% to 1% after oral administration of 3 mg, 7 mg and 14 mg of RYBELSUS. • 1% to 2% after oral administration of 1.5 mg, 4 mg and 9 mg of OZEMPIC tablets.
Projected row 1388
- Medicine slug
- sepiapterin
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
5 hours
- Numeric value
- 5
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fabfee2-9488-4d03-b203-8fa50f9a7f55 (opens source in a new tab)
Sepiapterin label
Version not recorded · Effective date not recorded
The terminal half-life of BH 4 is approximately 5 hours and the apparent clearance is 1498 (848) L/h in adult patients with PKU.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ac719c-49f0-4105-9c46-18c19583a5c2 (opens source in a new tab)
Sepiapterin label
Version not recorded · Effective date not recorded
The terminal half-life of BH 4 is approximately 5 hours and the apparent clearance is 1498 (848) L/h in adult patients with PKU.
Projected row 1389
- Medicine slug
- sepiapterin
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
15.4%
- Numeric value
- 15.4
- Unit
- %
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fabfee2-9488-4d03-b203-8fa50f9a7f55 (opens source in a new tab)
Sepiapterin label
Version not recorded · Effective date not recorded
Distribution Sepiapterin mean human plasma protein binding was 15.4% in the presence of 0.1% dithiothreitol (DTT) in the concentration range of 0.1 to 10 μM.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ac719c-49f0-4105-9c46-18c19583a5c2 (opens source in a new tab)
Sepiapterin label
Version not recorded · Effective date not recorded
Distribution Sepiapterin mean human plasma protein binding was 15.4% in the presence of 0.1% dithiothreitol (DTT) in the concentration range of 0.1 to 10 μM.
Projected row 1390
- Medicine slug
- sepiapterin
- Compared field
- tMax
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 2
- Source count
- 2
- Agreement rate
- 1
- Recorded readings
1 to 3 hours
- Numeric value
- 1
- Unit
- hours
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9fabfee2-9488-4d03-b203-8fa50f9a7f55 (opens source in a new tab)
Sepiapterin label
Version not recorded · Effective date not recorded
Analyte T max (hr) Median (Range) C max (ng/mL) Mean (SD) AUC inf ng*hr/mL) Mean (SD) AUC 24 (ng*hr/mL) Mean (SD) Sepiapterin N Results 29 2 (0.5, 6.1) 29 2.9 (1.6) NC 27 19.9 (18.3) BH 4 N Results 30 4 (2, 8) 30 432 (177) 19 3,626 (1267) 30 3,618 (1,699) Absorption The time to maximum plasma concentration (T max ) of sepiapterin is approximately 1 to 3 hours after oral administration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:32ac719c-49f0-4105-9c46-18c19583a5c2 (opens source in a new tab)
Sepiapterin label
Version not recorded · Effective date not recorded
Analyte T max (hr) Median (Range) C max (ng/mL) Mean (SD) AUC inf ng*hr/mL) Mean (SD) AUC 24 (ng*hr/mL) Mean (SD) Sepiapterin N Results 29 2 (0.5, 6.1) 29 2.9 (1.6) NC 27 19.9 (18.3) BH 4 N Results 30 4 (2, 8) 30 432 (177) 19 3,626 (1267) 30 3,618 (1,699) Absorption The time to maximum plasma concentration (T max ) of sepiapterin is approximately 1 to 3 hours after oral administration.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=1380Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.